Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain

• Published in: EJD. European journal of dermatology Vol. 25; no. 5; pp. 410 - 417
• Main Authors: Puig, Lluís, Camacho, Francisco, García-Patos, Vicente, Fernández-Díaz, Maria Luisa, Marquina, Amparo, García-Calvo, Carmen
• Format: Journal Article
• Language: English
• Published: Paris John Libbey Eurotext 01.09.2015
• Subjects: Adult; Analysis of Variance; Cohort Studies; Dermatology; Dose-Response Relationship, Drug; Drug Administration Schedule; Etanercept - therapeutic use; Female; Follow-Up Studies; Humans; Immunosuppressive Agents - therapeutic use; Male; Medicine; Medicine & Public Health; Middle Aged; Psoriasis - diagnosis; Psoriasis - drug therapy; Risk Assessment; Severity of Illness Index; Spain; Statistics, Nonparametric; Therapy; Time Factors; Treatment Outcome; etanercept; psoriasis; efficacy
• ISSN: 1167-1122; 1952-4013
• DOI: 10.1684/ejd.2015.2591

Background Information on the long-term efficacy of etanercept (ETN) treatment of moderate-to-severe psoriasis according to the Summary of Product Characteristics (SmPC) is scarce. Objectives We report the efficacy results of an observational clinical trial including 202 patients treated for 12 months with ETN according to SmPC. Methods Concomitant topical treatment was permitted throughout the study period. Efficacy assessment was done by intention-to-treat analysis with last observation carried forward. Results Mean%Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) decreased from 39.0% and 22.2% at baseline to 7.9% and 4.4%, respectively, at 12 months. Throughout the study duration, PASI 50, PASI 75 and PASI 90 response rates ranged from 72.8% to 95.7%, 55.6% to 84.3%, and 36.1% to 62.2%, respectively. Body mass index and body weight had minor effects on treatment efficacy. Conclusion ETN treatment according to the SmPC provided sustained improvement of psoriasis throughout one year.